Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 9/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 9/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | LYN | P07948 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.34 |
| ▸ | SIK1 | P57059 | 2/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.34 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.34 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27655692 | 0.86 | DYRK1A (0.43) | DYRK1AMAPTKDR | |
| SCHEMBL952876 | 0.84 | GRM5 (0.37) | MAPTGRM5CPT1ACPT1B | |
| SCHEMBL951836 | 0.84 | GRM5 (0.38) | MAPTGRM5ABL1CPT1ACPT1B | |
| SCHEMBL954077 | 0.84 | NPC1 (0.39) | MAPTGRM5 | |
| SCHEMBL951815 | 0.83 | GRM5 (0.39) | MAPTGRM5CPT1ACPT1B | |
| SCHEMBL954359 | 0.81 | GRM5 (0.36) | MAPTGRM5CPT1ACPT1B | |
| SCHEMBL951128 | 0.81 | ABL1 (0.42) | DYRK1AMAPTKDRGRM5ABL1 | |
| SCHEMBL954050 | 0.81 | GRM5 (0.37) | IKBKETBK1DYRK1AMAP4K4MAPT | |
| SCHEMBL4531463 | 0.80 | GRM5 (0.36) | IKBKETBK1MAPTGRM5TGFBR1 | |
| SCHEMBL953701 | 0.80 | PIK3C3 (0.41) | IKBKETBK1GSK3BDYRK1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| CN-1933834-A | Use of indazolecarboxamide derivatives for the preparation of a medicament for the treatment and prevention of malaria | SANOFI AVENTIS (FR) | 2007-03-21 | — | — | CN | disclosed |
| EP-1727544-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | Sanofi-Aventis (FR) | 2006-12-06 | — | — | EP | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | IKBKE 732/4885TBK1 3077/4885GSK3B 2803/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | IKBKE 732/4885TBK1 3077/4885GSK3B 2803/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | IKBKE 295/4885TBK1 3116/4885GSK3B 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.